Company Profile
Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, a member of Roche group, in January 2012 and started operations on July 2, 2012.
CPR conducts drug discovery research creating new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets and diseases using our proprietary antibody engineering technologies. CPR also conducts research utilizing our cyclic peptide drug discovery platform.
Company Name
Chugai Pharmabody Research Pte. Ltd.
(“Pharmabody” is coined from the words pharmaceutical and antibody.)
Establishment
January 10, 2012
Location
1A Science Park Drive, #07-21, Geneo, Singapore 119314
Commencement of Operations
July 2, 2012
Capital
S$ 21.5 million
CEO
Futa Mimoto Ph.D.
Shareholder
Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.
Board of Directors
Sir David Lane, Chairman of the Board
Futa Mimoto, Director and CEO
Hitoshi Iikura, Director
Ashok Venkitaraman, Director
Target Headcount
155 employees